Weight loss drug's hidden toll: new study tracks muscle loss

NCT ID NCT07272837

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses advanced MRI scans to track changes in muscle and fat in the body and heart over 12 months in 50 adults starting semaglutide for type 2 diabetes or weight loss. Participants will undergo MRI scans, physical tests, blood samples, and questionnaires. The goal is to understand how semaglutide affects muscle health to ensure long-term well-being.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mazankowski Alberta Heart Institute

    RECRUITING

    Edmonton, Alberta, T6G 0M9, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••